Mesoporous Silica Nanoparticles as a Potential Platform for Vaccine Development against Tuberculosis
Abstract
:1. Introduction
2. Materials and Methods
2.1. Reagents and Equipment
2.2. Materials Synthesis
2.3. Cytotoxicity Assay
2.4. ELISA
3. Results and Discussion
3.1. Immunomodulatory Proteins
3.2. Synthesis and Characterization of the Immunomodulatory Nanosystems
3.3. Cell Viability
3.4. Evaluation of Immunostimulatory Capacity of MSNs-ProtMtb Nanosystems
4. Conclusions
Supplementary Materials
Author Contributions
Funding
Conflicts of Interest
References
- World Health Organization (WHO). Global Tuberculosis Report; WHO: Geneva, Switzerland, 2019. [Google Scholar]
- Kaufmann, S.H. Future vaccination strategies against tuberculosis: Thinking outside the box. Immunity 2010, 33, 567–577. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Prados-Rosales, R.; Baena, A.; Martinez, L.R.; Luque-Garcia, J.L.; Kalscheuer, R.; Veeraraghavan, U.; Camara, C.; Nosanchuk, J.D.; Besra, G.S.; Chen, B.; et al. Mycobacteria release active membrane vesicles that modulate immune responses in a TLR2-dependent manner in mice. J. Clin. Investig. 2011, 121, 1471–1483. [Google Scholar] [CrossRef] [PubMed]
- Brown, L.; Wolf, J.; Prados-Rosales, R.; Casadevall, A. Through the wall: Extracellular vesicles in Gram-positive bacteria, mycobacteria and fungi. Nat. Rev. Microbiol. 2015, 13, 620–630. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Prados-Rosales, R.; Carreño, L.J.; Batist-Gonzalez, A.; Baena, A.; Venkataswamy, M.M.; Xu, J.; Yu, X.; Wallstrom, G.; Magee, D.M.; LaBaer, J.; et al. Mycobacterial membrane vesicles administered systemically in mice induce a protective immune response to surface compartments of mycobacterium tuberculosis. mBio 2014, 5, e01921-14. [Google Scholar] [CrossRef] [Green Version]
- Rodriguez, G.M.; Prados-Rosales, R. Functions and importance of mycobacterial extracellular vesicles. Appl. Microbiol. Biotechnol. 2016, 100, 3887–3892. [Google Scholar] [CrossRef]
- Mishra, M.; Kumar, P.; Rajawat, J.S.; Malik, R.; Sharma, G.; Modgil, A. Nanotechnology: Revolutionizing the science of drug delivery. Curr. Pharm. Des. 2018, 24, 5086–5107. [Google Scholar] [CrossRef]
- Wong, I.Y.; Bhatia, S.N.; Toner, M. Nanotechnology: Emerging tools for biology and medicine. Genes Dev. 2013, 27, 2397–2408. [Google Scholar] [CrossRef] [Green Version]
- Machuca, A.; Garcia-Calvo, E.; Anunciacao, D.S.; Luque-Garcia, J.L. Rhodium nanoparticles as a novel photosensitizing agent in photodynamic therapy against cancer. Chem. Eur. J. 2020, 26, 7685–7691. [Google Scholar] [CrossRef]
- Estevez, H.; Garcia-Lidon, J.C.; Luque-Garcia, J.L.; Camara, C. Effects of chitosan-stabilized selenium nanoparticles on cell proliferation, apoptosis and cell cycle patter in HepG2 cells: Comparison with other selenospecies. Colloids Surf. B 2014, 122, 184–193. [Google Scholar] [CrossRef]
- Estevez, H.; Palacios, A.; Gil, D.; Anguita, J.; Vallet-Regi, M.; Gonzalez, B.; Prados-Rosales, R.; Luque-Garcia, J.L. Antimycobacterial effect of selenium nanoparticles on mycobacterium tuberculosis. Frontiers Microbiol. 2020, 11, 800. [Google Scholar] [CrossRef]
- Montalvo-Quirós, S.; Gomez-Graña, S.; Vallet-Regi, M.; Prados-Rosales, R.C.; Gonzalez, B.; Luque-Garcia, J.L. Mesoporous silica nanoparticles containing silver as novel antimycobacterial agents against Mycobacterium tuberculosis. Colloids Surf. B 2021, 197, 111405. [Google Scholar] [CrossRef] [PubMed]
- Costa-Gouveia, J.; Aínsa, J.A.; Brodin, P.; Lucía, A. How can nanoparticles contribute to antituberculosis therapy? Drug Discov. Today 2017, 22, 600–607. [Google Scholar] [CrossRef] [PubMed]
- Ballester, M.; Nembrini, C.; Dhar, N.; De Titta, A.; De Piano, C.; Pasquier, M.; Simeoni, E.; Van Der Vlies, A.J.; McKinney, J.D.; Hubbell, J.A.; et al. Nanoparticle conjugation and pulmonary delivery enhance the protective efficacy of Ag85B and CpG against tuberculosis. Vaccine 2011, 29, 6959–6966. [Google Scholar] [CrossRef] [PubMed]
- Villegas, M.R.; Baeza, A.; Vallet-Regí, M. Nanotechnological strategies for protein delivery. Molecules 2018, 23, 1008. [Google Scholar] [CrossRef] [Green Version]
- Vallet-Regí, M.; Ramila, A.; Del Real, R.P.; Pérez-Pariente, J. A new property of MCM-41: Drug delivery system. Chem. Mater. 2001, 13, 308–311. [Google Scholar] [CrossRef]
- Castillo, R.; Lozano, D.; González, B.; Manzano, M.; Izquierdo, I.; Vallet-Regí, M. Advances in mesoporous silica nanoparticles for targeted stimuli-responsive drug delivery: An update. Expert Opin. Drug. Deliv. 2019, 16, 415–439. [Google Scholar] [CrossRef]
- Manzano, M.; Vallet-Regí, M. Mesoporous silica nanoparticles for drug delivery. Adv. Funct. Mater. 2020, 30, E1902634. [Google Scholar] [CrossRef]
- Moreno, V.M.; Álvarez, E.; Izquierdo-Barba, I.; Baeza, A.; Serrano-López, J.; Vallet-Regí, M. Bacteria as nanoparticles carrier for enhancing penetration in a tumoral matrix model. Adv. Mater. Interfaces 2020, 7, 1901942. [Google Scholar] [CrossRef]
- Lu, J.; Liong, M.; Li, Z.; Zink, J.I.; Tamanoi, F. Biocompatibility, biodistribution, and drug-delivery efficiency of mesoporous silica nanoparticles for cancer therapy in animals. Small 2010, 6, 1794–1805. [Google Scholar] [CrossRef] [Green Version]
- Xu, C.; Lei, C.; Yu, C. Mesoporous silica nanoparticles for protein protection and delivery. Front. Chem. 2019, 7, 290. [Google Scholar] [CrossRef] [Green Version]
- Montalvo-Quirós, S.; Aragoneses-Cazorla, G.; García-Alcalde, L.; Vallet-Regí, M.; González, B.; Luque-García, J.L. Cancer cell targeting and therapeutic delivery of silver nanoparticles by mesoporous silica nanocarriers: Insights into the action mechanisms using quantitative proteomics. Nanoscale 2019, 11, 4531–4545. [Google Scholar] [CrossRef] [PubMed]
- Villegas, M.R.; Baeza, A.; Vallet Regí, M. Hybrid collagenase nanocapsules for enhanced nanocarrier penetration in tumoral tissues. ACS Appl. Mater. Interfaces 2015, 7, 24075–24081. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Villegas, M.R.; Baeza, A.; Noureddine, A.; Durfee, P.; Butler, K.; Agola, J.; Brinker, J.C.; Vallet-Regí, M. Multifunctional protocells for enhanced penetration in 3D extracellular tumoral matrices. Chem. Mater. 2018, 30, 112–120. [Google Scholar] [CrossRef]
- Clemens, D.L.; Lee, B.-Y.; Xue, M.; Thomas, C.R.; Meng, H.; Ferris, D.; Nel, A.E.; Zink, J.I.; Horwitz, M.A. Targeted intracellular delivery of antituberculosis drugs to mycobacterium tuberculosis-infected macrophages via functionalized mesoporous silica nanoparticles. Antimicrob. Agents Chemother. 2012, 56, 2535–2545. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hwang, A.A.; Lee, B.-Y.; Clemens, D.L.; Dillon, B.J.; Zink, J.I.; Horwitz, M.A. pH-Responsive Isoniazid-Loaded Nanoparticles Markedly Improve Tuberculosis Treatment in Mice. Small 2015, 11, 5066–5078. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Li, X.; Xue, M.; Raabe, O.G.; Aaron, H.L.; Eisen, E.A.; Evans, J.E.; Hayes, F.A.; Inaga, S.; Tagmount, A.; Takeuchi, M.; et al. Aerosol droplet delivery of mesoporous silica nanoparticles: A strategy for respiratory-based therapeutics. Nanomedicine 2015, 11, 1377–1385. [Google Scholar] [CrossRef] [Green Version]
- Mody, K.T.; Popat, A.; Mahony, D.; Cavallaro, A.S.; Yu, C.; Mitter, N. Mesoporous silica nanoparticles as antigen carriers and adjuvants for vaccine delivery. Nanoscale 2013, 5, 5167–5179. [Google Scholar] [CrossRef]
- Carvalho, L.V.; Ruiz, R.; Scaramuzzi, K.; Marengo, E.B.; Matos, J.R.; Tambourgi, D.V.; Fantini, M.C.; Sant’Anna, O.A. Immunological parameters related to the adjuvant effect of the ordered mesoporous silica SBA-15. Vaccine 2010, 28, 7829–7836. [Google Scholar] [CrossRef]
- Liu, T.; Liu, H.; Fu, C.; Li, L.; Chen, D.; Zhang, Y.; Tang, F. Silica nanorattle with enhanced protein loading: A potential vaccine adjuvant. J. Colloid Interface Sci. 2013, 400, 168–174. [Google Scholar] [CrossRef]
- Skrastina, D.; Petrovskis, I.; Lieknina, I.; Bogans, J.; Renhofa, R.; Ose, V.; Dishlers, A.; Dekhtyar, Y.; Pumpens, P. Silica nanoparticles as the adjuvant for the immunisation of mice using hepatitis B core virus-like particles. PLoS ONE 2014, 9, e114006. [Google Scholar] [CrossRef] [Green Version]
- Lu, Y.; Yang, Y.; Gu, Z.; Zhang, J.; Song, H.; Xiang, G.; Yu, C. Glutathione-depletion mesoporous organosilica nanoparticles as a self-adjuvant and co-delivery platform for enhanced cancer immunotherapy. Biomaterials 2018, 175, 82–92. [Google Scholar] [CrossRef] [PubMed]
- Du, G.; Woythe, L.; Van Der Maaden, K.; Leone, M.; Romeijn, S.; Kros, A.; Kersten, G.; Jiskoot, W.; Bouwstra, J.A. Coated and Hollow Microneedle-Mediated Intradermal Immunization in Mice with Diphtheria Toxoid Loaded Mesoporous Silica Nanoparticles. Pharm. Res. 2018, 35, 189. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Oliveira, D.C.D.P.; De Barros, A.L.B.; Belardi, R.M.; De Goes, A.M.; Souza, B.K.D.O.; Soares, D.C.F. Mesoporous silica nanoparticles as a potential vaccine adjuvant against Schistosoma mansoni. J. Drug Deliv. Sci. Technol. 2016, 35, 234–240. [Google Scholar] [CrossRef]
- Aguilar-López, B.A.; Correa, F.; Moreno-Altamirano, M.M.B.; Espitia, C.; Hernandez-Longoria, R.; Oliva-Ramirez, J.; Padierna-Olivos, J.; Sancgez-Garcia, F.J. LprG and PE_PGRS33 Mycobacterium tuberculosis virulence factors induce differential mitochondrial dynamics in macropahges. Scan J. Immunol. 2019, 89, e12728. [Google Scholar] [CrossRef] [Green Version]
- Martínez, A.; Fuentes-Paniagua, E.; Baeza, A.; Sánchez-Nieves, J.; Cicuéndez, M.; Gómez, R.; de la Mata, F.J.; González, B.; Vallet-Regí, M. Mesoporous silica nanoparticles decorated with carbosilane dendrons as new non-viral oligonucleotide delivery carriers. Chem. Eur. J. 2015, 21, 15651–15666. [Google Scholar] [CrossRef] [Green Version]
- Lee, J.; Kim, S.H.; Choi, D.S.; Lee, J.S.; Kim, D.K.; Go, G.; Park, S.M.; Kim, S.H.; Shin, J.H.; Chang, C.L.; et al. Proteomic analysis of extracellular vesicles derived from Mycobacterium tuberculosis. Proteomics 2015, 15, 3331–3337. [Google Scholar] [CrossRef]
- Lim, M.; Stein, A. Comparative studies of grafting and direct syntheses of inorganic-organic hybrid mesoporous materials. Chem. Mater. 1999, 11, 3285–3295. [Google Scholar] [CrossRef]
- de Juan, F.; Ruiz-Hitzky, E. Selective functionalization of mesoporous silica. Adv. Mater. 2000, 12, 430–432. [Google Scholar] [CrossRef]
- IEPAg85B Calculated from the Protein Sequence NCBI GenBank (Ag85B, A5U3Q3.1) and the Expasy Program. Available online: https://web.expasy.org/protparam/ (accessed on 26 March 2015).
- IEPLprG Calculated from the Protein Sequence NCBI GenBank (LprG, ANZ82088.1) and the Expasy Program. Available online: https://web.expasy.org/protparam/ (accessed on 26 March 2015).
- IEPLprA Calculated from the Protein Sequence NCBI GenBank (LprA, ANZ81937.1) and the Expasy Program. Available online: https://web.expasy.org/protparam/ (accessed on 26 March 2015).
- Luo, Z.; Hu, Y.; Xin, R.; Zhang, B.; Li, J.; Ding, X.; Hou, Y.; Yang, L.; Cai, K. Surface functionalized mesoporous silica nanoparticles with natural proteins for reduced immunotoxicity. J. Biomed. Mater. Res. Part A 2014, 102, 3781–3794. [Google Scholar] [CrossRef]
- Nieto, A.; Colilla, M.; Balas, F.; Vallet-Regí, M. Surface electrochemistry of mesoporous silicas as a key factor in the design of tailored delivery devices. Langmuir 2010, 26, 5038–5049. [Google Scholar] [CrossRef]
- Rosenholm, J.M.; Sahlgren, C.; Lindén, M. Towards multifunctional, targeted drug delivery systems using mesoporous silica nanoparticles—Opportunities & challenges. Nanoscale 2010, 2, 1870–1883. [Google Scholar] [CrossRef] [PubMed]
- González, B.; Colilla, M.; Díez, J.; Pedraza, D.; Guembe, M.; Izquierdo-Barba, I.; Vallet-Regí, M. Mesoporous silica nanoparticles decorated with polycationic dendrimers for infection treatment. Acta Biomater. 2018, 68, 261–271. [Google Scholar] [CrossRef]
- Chensue, S.W.; Warmington, K.; Ruth, J.; Lincoln, P.; Kuo, M.C.; Kunkel, S.L. Cytokine responses during mycobacterial and schistosomal antigen-induced pulmonary granuloma formation. Production of Th1 and Th2 cytokines and relative contribution of tumor necrosis factor. Am. J. Pathol. 1994, 145, 1105–1113. [Google Scholar] [PubMed]
- Chensue, S.W.; Warmington, K.S.; Ruth, J.H.; Lincoln, P.; Kunkel, S.L. Cytokine function during mycobacterial and schistosomal antigen-induced pulmonary granuloma formation. Local and regional participation of IFN-gamma, IL-10 and TNF. J. Immunol. 1995, 154, 5969–5976. [Google Scholar]
- Gordon, S. Alternative activation of macrophages. Nat. Rev. Immunol. 2003, 3, 23–35. [Google Scholar] [CrossRef] [PubMed]
- Lesniak, A.; Fenaroli, F.; Monopoli, M.P.; Åberg, C.; Dawson, K.A.; Salvati, A. Effects of the Presence or Absence of a Protein Corona on Silica Nanoparticle Uptake and Impact on Cells. ACS Nano 2012, 6, 5845–5857. [Google Scholar] [CrossRef] [PubMed]
- Salvati, A.; Pitek, A.S.; Monopoli, M.P.; Prapainop, K.; Baldelli Bombelli, F.; Hristov, D.R.; Kelly, P.M.; Åberg, C.; Mahon, E.; Dawson, K.A. Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface. Nat. Nanotechnol. 2013, 8, 137–143. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Material | Org. Content (wt%) | [ProteinMtb] Nominal (μg/mL) 2 | [Non-Anchored ProteinMtb] (μg/mL) | % Anchored ProteinMtb |
---|---|---|---|---|
MSNs | 3.9 | --- | --- | --- |
MSNs-COOHext-CTAB | 34.6 1 | --- | --- | --- |
MSNs-COOHext | 5.4 1 | --- | --- | --- |
MSNs-Ag85B | 8.1 1 | 91.9 | 0.64 | 99% |
MSNs-LprG | 8.7 1 | 67.47 | 0.56 | 99% |
MSNs-LprA | 8.6 1 | 71.96 | 3.89 | 95% |
Material | ζ-Potential (mV) | Hydrodynamic Size (nm) |
---|---|---|
MSNs | −19 ± 8 | 176 ± 13 |
MSNs-COOHext | −28 ± 7 | 223 ± 29 |
MSNs-Ag85B | −24 ± 6 | 178 ± 18 |
MSNs-LprG | −27 ± 7 | 192 ± 18 |
MSNs-LprA | −25 ± 8 | 182 ± 20 |
Material | δ, ppm (Peak Area, %) | Peak Area Ratio | δ (ppm) | Peak Area Ratio | |||
---|---|---|---|---|---|---|---|
Q2 | Q3 | Q4 | (Q2 + Q3)/Q4 | T2 | T3 | Q/T | |
MSNs | −93.2 (6.2) | −102.3 (44.6) | −112.0 (49.1) | 1.0 | --- | --- | --- |
MSNs-COOHext | −93.6 (3.2) | −102.7 (36.5) | −112.0 (60.2) | 0.6 | −57.8 | −66.9 | 15.3 |
MSNs-LprG | −93.7 (2.7) | −102.6 (35.5) | −112.5 (61.8) | 0.6 | −57.3 | −66.7 | 15.2 |
Material | SBET (m2/g) | Dp (nm) | VT (cm3/g) | VP (cm3/g) |
---|---|---|---|---|
MSNs | 1368.4 | 2.73 | 1.64 | 1.09 |
MSNs-CTAB | 104.2 | --- | --- | --- |
MSNs-COOHext | 557.2 | 2.03 | 0.391 | 0.274 |
MSNs-LprG | 440.6 | 1.20 | 0.389 | 0.218 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Montalvo-Quirós, S.; Vallet-Regí, M.; Palacios, A.; Anguita, J.; Prados-Rosales, R.C.; González, B.; Luque-Garcia, J.L. Mesoporous Silica Nanoparticles as a Potential Platform for Vaccine Development against Tuberculosis. Pharmaceutics 2020, 12, 1218. https://doi.org/10.3390/pharmaceutics12121218
Montalvo-Quirós S, Vallet-Regí M, Palacios A, Anguita J, Prados-Rosales RC, González B, Luque-Garcia JL. Mesoporous Silica Nanoparticles as a Potential Platform for Vaccine Development against Tuberculosis. Pharmaceutics. 2020; 12(12):1218. https://doi.org/10.3390/pharmaceutics12121218
Chicago/Turabian StyleMontalvo-Quirós, Sandra, María Vallet-Regí, Ainhoa Palacios, Juan Anguita, Rafael C. Prados-Rosales, Blanca González, and Jose L. Luque-Garcia. 2020. "Mesoporous Silica Nanoparticles as a Potential Platform for Vaccine Development against Tuberculosis" Pharmaceutics 12, no. 12: 1218. https://doi.org/10.3390/pharmaceutics12121218